Predictors of Survival of Advanced Renal Cell Carcinoma: Long-Term Results From Southwest Oncology Group Trial S8949

Primo N Lara, Catherine M. Tangen, Sarah J. Conlon, Robert C. Flanigan, E. David Crawford

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Purpose: S8949 demonstrated improved overall survival for debulking nephrectomy in interferon treated patients with advanced renal cell carcinoma. We present an updated analysis of S8949, now with a median followup of 9 years. We explored clinical predictors of overall survival. Materials and Methods: Univariate and multivariate Cox regression analysis was performed to evaluate the impact of clinical variables potentially influencing survival. Results: Of 246 patients 241 were eligible and randomized to interferon with or without nephrectomy. Patients randomized to nephrectomy continued to have improved overall survival (HR 0.74, 95% CI 0.57-0.96, p = 0.022). Multivariate analysis showed that performance status 1 vs 0 (HR 1.95, p <0.0001), high alkaline phosphatase (HR 1.5, p = 0.002) and lung metastasis only (HR 0.73, p = 0.028) were overall survival predictors. There was no evidence of an interaction of performance status, measurable disease or lung metastases with nephrectomy (each p >0.30). In a patient subset that survived at least 90 days after randomization early progressive disease within 90 days was prognostic of overall survival in a multivariate model (HR 2.1, p <0.0001), as was performance status (HR 1.7, p = 0.0006). Conclusions: Nephrectomy prolonged long-term overall survival in this updated analysis, supporting its role as standard therapy in patients with advanced renal cell carcinoma. A nephrectomy benefit was seen across all prespecified patient subsets. Early progressive disease and performance status were strong predictors of overall survival. These results support efforts to identify biomarkers of renal cell carcinoma resistance to treatment and early progressive disease to facilitate rational patient selection for systemic therapy.

Original languageEnglish (US)
Pages (from-to)512-517
Number of pages6
JournalJournal of Urology
Volume181
Issue number2
DOIs
StatePublished - Feb 2009

Fingerprint

Renal Cell Carcinoma
Nephrectomy
Survival
Interferons
Random Allocation
Patient Selection
Therapeutics
Multivariate Analysis
Biomarkers
Regression Analysis

Keywords

  • carcinoma
  • inteferons
  • kidney
  • mortality
  • nephrectomy
  • renal cell

ASJC Scopus subject areas

  • Urology

Cite this

Predictors of Survival of Advanced Renal Cell Carcinoma : Long-Term Results From Southwest Oncology Group Trial S8949. / Lara, Primo N; Tangen, Catherine M.; Conlon, Sarah J.; Flanigan, Robert C.; Crawford, E. David.

In: Journal of Urology, Vol. 181, No. 2, 02.2009, p. 512-517.

Research output: Contribution to journalArticle

Lara, Primo N ; Tangen, Catherine M. ; Conlon, Sarah J. ; Flanigan, Robert C. ; Crawford, E. David. / Predictors of Survival of Advanced Renal Cell Carcinoma : Long-Term Results From Southwest Oncology Group Trial S8949. In: Journal of Urology. 2009 ; Vol. 181, No. 2. pp. 512-517.
@article{4b0df035f2ad476b9b2705fe82c1578c,
title = "Predictors of Survival of Advanced Renal Cell Carcinoma: Long-Term Results From Southwest Oncology Group Trial S8949",
abstract = "Purpose: S8949 demonstrated improved overall survival for debulking nephrectomy in interferon treated patients with advanced renal cell carcinoma. We present an updated analysis of S8949, now with a median followup of 9 years. We explored clinical predictors of overall survival. Materials and Methods: Univariate and multivariate Cox regression analysis was performed to evaluate the impact of clinical variables potentially influencing survival. Results: Of 246 patients 241 were eligible and randomized to interferon with or without nephrectomy. Patients randomized to nephrectomy continued to have improved overall survival (HR 0.74, 95{\%} CI 0.57-0.96, p = 0.022). Multivariate analysis showed that performance status 1 vs 0 (HR 1.95, p <0.0001), high alkaline phosphatase (HR 1.5, p = 0.002) and lung metastasis only (HR 0.73, p = 0.028) were overall survival predictors. There was no evidence of an interaction of performance status, measurable disease or lung metastases with nephrectomy (each p >0.30). In a patient subset that survived at least 90 days after randomization early progressive disease within 90 days was prognostic of overall survival in a multivariate model (HR 2.1, p <0.0001), as was performance status (HR 1.7, p = 0.0006). Conclusions: Nephrectomy prolonged long-term overall survival in this updated analysis, supporting its role as standard therapy in patients with advanced renal cell carcinoma. A nephrectomy benefit was seen across all prespecified patient subsets. Early progressive disease and performance status were strong predictors of overall survival. These results support efforts to identify biomarkers of renal cell carcinoma resistance to treatment and early progressive disease to facilitate rational patient selection for systemic therapy.",
keywords = "carcinoma, inteferons, kidney, mortality, nephrectomy, renal cell",
author = "Lara, {Primo N} and Tangen, {Catherine M.} and Conlon, {Sarah J.} and Flanigan, {Robert C.} and Crawford, {E. David}",
year = "2009",
month = "2",
doi = "10.1016/j.juro.2008.10.021",
language = "English (US)",
volume = "181",
pages = "512--517",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Predictors of Survival of Advanced Renal Cell Carcinoma

T2 - Long-Term Results From Southwest Oncology Group Trial S8949

AU - Lara, Primo N

AU - Tangen, Catherine M.

AU - Conlon, Sarah J.

AU - Flanigan, Robert C.

AU - Crawford, E. David

PY - 2009/2

Y1 - 2009/2

N2 - Purpose: S8949 demonstrated improved overall survival for debulking nephrectomy in interferon treated patients with advanced renal cell carcinoma. We present an updated analysis of S8949, now with a median followup of 9 years. We explored clinical predictors of overall survival. Materials and Methods: Univariate and multivariate Cox regression analysis was performed to evaluate the impact of clinical variables potentially influencing survival. Results: Of 246 patients 241 were eligible and randomized to interferon with or without nephrectomy. Patients randomized to nephrectomy continued to have improved overall survival (HR 0.74, 95% CI 0.57-0.96, p = 0.022). Multivariate analysis showed that performance status 1 vs 0 (HR 1.95, p <0.0001), high alkaline phosphatase (HR 1.5, p = 0.002) and lung metastasis only (HR 0.73, p = 0.028) were overall survival predictors. There was no evidence of an interaction of performance status, measurable disease or lung metastases with nephrectomy (each p >0.30). In a patient subset that survived at least 90 days after randomization early progressive disease within 90 days was prognostic of overall survival in a multivariate model (HR 2.1, p <0.0001), as was performance status (HR 1.7, p = 0.0006). Conclusions: Nephrectomy prolonged long-term overall survival in this updated analysis, supporting its role as standard therapy in patients with advanced renal cell carcinoma. A nephrectomy benefit was seen across all prespecified patient subsets. Early progressive disease and performance status were strong predictors of overall survival. These results support efforts to identify biomarkers of renal cell carcinoma resistance to treatment and early progressive disease to facilitate rational patient selection for systemic therapy.

AB - Purpose: S8949 demonstrated improved overall survival for debulking nephrectomy in interferon treated patients with advanced renal cell carcinoma. We present an updated analysis of S8949, now with a median followup of 9 years. We explored clinical predictors of overall survival. Materials and Methods: Univariate and multivariate Cox regression analysis was performed to evaluate the impact of clinical variables potentially influencing survival. Results: Of 246 patients 241 were eligible and randomized to interferon with or without nephrectomy. Patients randomized to nephrectomy continued to have improved overall survival (HR 0.74, 95% CI 0.57-0.96, p = 0.022). Multivariate analysis showed that performance status 1 vs 0 (HR 1.95, p <0.0001), high alkaline phosphatase (HR 1.5, p = 0.002) and lung metastasis only (HR 0.73, p = 0.028) were overall survival predictors. There was no evidence of an interaction of performance status, measurable disease or lung metastases with nephrectomy (each p >0.30). In a patient subset that survived at least 90 days after randomization early progressive disease within 90 days was prognostic of overall survival in a multivariate model (HR 2.1, p <0.0001), as was performance status (HR 1.7, p = 0.0006). Conclusions: Nephrectomy prolonged long-term overall survival in this updated analysis, supporting its role as standard therapy in patients with advanced renal cell carcinoma. A nephrectomy benefit was seen across all prespecified patient subsets. Early progressive disease and performance status were strong predictors of overall survival. These results support efforts to identify biomarkers of renal cell carcinoma resistance to treatment and early progressive disease to facilitate rational patient selection for systemic therapy.

KW - carcinoma

KW - inteferons

KW - kidney

KW - mortality

KW - nephrectomy

KW - renal cell

UR - http://www.scopus.com/inward/record.url?scp=58149183664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149183664&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2008.10.021

DO - 10.1016/j.juro.2008.10.021

M3 - Article

C2 - 19100570

AN - SCOPUS:58149183664

VL - 181

SP - 512

EP - 517

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -